Skip to main content
. 2019 May 24;10:1128. doi: 10.3389/fimmu.2019.01128

Table 2.

Pharmacological mediators with their target molecule, concentration, pretreatment as well as commercial origin.

Inhibitor Target Concentration (μM) Pre-treatment (h) Origin
U0126 MEK 1/2 5 1 New England Biolabs, Ipswich, USA
PP2 Src-family kinases 10 1 Merck Millipore, Billerica, USA
BAPTA-AM Intracellular Ca2+ chelation 200 4 Merck Millipore, Billerica, USA
Erlotinib EGFR 2.5 1 Santa Cruz Biotechnology,Santa Cruz, USA